Strategic partnerships Leverage recent SGD Pharma collaboration to position Prince as a preferred integration partner for ready-to-use Type I glass primary packaging in North America, targeting complex chronic conditions and nasal delivery platforms.

Expansion opportunities Target medical device manufacturers exploring alternative sterilization methods such as vaporized hydrogen peroxide to Ethylene Oxide, aligning with Prince’s VH2O2 capabilities and MD&M West engagements to credentialize as a go-to sterilization provider.

In-house capabilities Highlight in-house low-temperature hydrogen peroxide sterilization and WFI washing services to capture customers seeking integrated sterilization and cleanliness workflows, reducing bioburden and endotoxin risk pre-sterilization.

Awards and credibility Utilize the 2024 contract sterilization service company of the year recognition and ongoing industry engagements to build case studies and outbound messaging that accelerates outreach to pharmaceutical and medical device firms seeking validated partners.

Growth funding signals Leverage the partnership with Vance Street Capital and the company’s mid-market revenue profile to approach growth-stage manufacturers looking for scalable sterilization and packaging capacity, emphasizing investment-backed expansion and reliability.